Therapeutic | Anselamimab |
Target | Light Chain Amyloid Fibrils |
Heavy Chain | QVQLKESGPGLVAPSQSLSITCTVSGFSLSSYGVSWVRQPPGKGLEWLGVIWGDGSTNYHPNLMSRLSISKDISKSQVLFKLNSLQTDDTATYYCVTLDYWGQGTSVTVSS |
Light Chain | DVVMTQTPLSLPVSLGDQASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGLYFCFQTTYVPNTFGGGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (August '23) | Phase-III |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2021 |
INN Year Recommended | 2022 |
Companies Involved | Caelum Biosciences |
Conditions Approved | na |
Conditions Active | AA amyloidosis |
Conditions Discontinued | na |
Notes | Oct '22: Amended target. Targets a conserved epitope across light chain amyloid fibrils: Am J Pathol. 2000;157(4):1239–46;Clin Cancer Res. 2003;9(10):3831S-3838S;Biochemistry. 2007;46(5):1240–7. |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]